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What are the novel findings of this work?   
This is the first systematic review assessing the incremental yield of antenatal exome 
sequencing over chromosome microarray/karyotype in prenatally diagnosed congenital 
heart disease. 
What are the clinical implications of this work? 
Dependent on the presence of robust pathways, exome sequencing may be considered in 
prenatal congenital heart disease, with particular consideration for not just those with 








OBJECTIVES:  To determine the yield of antenatal exome sequencing (ES) over chromosome 
microarray (CMA) / conventional karyotyping in; (i) any prenatally diagnosed congenital 
heart disease (CHD); (ii) isolated CHD; (iii) multi-system CHD and; (iv) CHD by phenotypic 
subgroup.   
METHODS:  A prospective cohort study of 197 trios undergoing ES following CMA/karyotype 
because CHD was identified prenatally and a systematic review of the literature was 
performed.  MEDLINE, EMBASE and CINAHL (2000–Oct 2019) databases were searched 
electronically.  Selected studies included those with; (i) >3 cases; (ii) initiation of testing 
based upon a prenatal phenotype only and; (iii) where CMA/karyotyping was negative.  
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RESULTS:  In our cohort ES gave an additional diagnostic yield in; (i) all CHD; (ii) isolated CHD 
and; (iii) multi-system CHD of 12.7% (n=25/197), 11.5% (n=14/122) and 14.7% (n=11/75) 
(p=0.81).  The pooled incremental yields for the aforementioned categories from 18-studies 
(n=636) were 21% (95% CI, 15-27%), 11% (95% CI, 7-15%) and 37% (95% CI, 18%-56%) 
respectively.  This did not differ significantly when sub-analyses were limited to studies 
including >20 cases.  In instances of multi-system CHD in the primary analysis, the 
commonest extra-cardiac anomalies associated with a pathogenic variant were those 
affecting the genitourinary system 44.2% (n=23/52).  Cardiac shunt lesions had the greatest 
incremental yield, 41% (95% CI, 19-63%), followed by right-sided lesions 26% (95% CI, 9-
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43%).   In the majority of instances pathogenic variants occurred de novo and in autosomal 
dominant (monoallelic) disease genes (68/96; 70.8%).  The commonest monogenic 
syndrome identified was Kabuki syndrome (n=19/96; 19.8%).   
CONCLUSIONS:  Despite the apparent incremental yield of prenatal exome sequencing 
in congenital heart disease, the routine application of such a policy would require the 
adoption of robust bioinformatic, clinical and ethical pathways.  Whilst the greatest 
yield is with multi-system anomalies, consideration may also be given to performing ES in 
the presence of isolated cardiac abnormalities.   
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INTRODUCTION  
Congenital heart disease (CHD) complicates 1% of live-born neonates and is associated with 
significantly high rates of perinatal morbidity and mortality.1,2  Prenatal detection of CHD 
and establishment of a unifying genetic diagnosis can inform prenatal management, 
optimise post-natal outcome and aid in the counselling of parents in both index and 
subsequent pregnancies.3  Of all prenatally diagnosed CHD, 2/3 tends to be isolated while 
1/3 can be associated with extra-cardiac anomalies (ECAs).4  Aneuploidy is present in 
between 28-45% of prenatally diagnosed CHD, with at least one ECA present in as many as 
98% of such cases.3  Copy number variation (CNV) can be present in a further 2-25%.3  The 
additional proportion of CHD caused by monogenic Mendelian disorders is traditionally 
thought to be ~5% although results vary.3  Since the introduction of exome sequencing (ES), 
large prospective studies suggest that this proportion is greater.5,6  It has been proposed 
that a significant number of identified variants in CHD within the pediatric population are de 
novo in nature, most notably when there are co-existing neurodevelopmental and ECAs.7,8  
There are a paucity of studies which have formally assessed the diagnostic yield offered 
from ES over standard chromosome microarray(CMA)/karyotype in prenatally diagnosed 
CHD and there is no evidence to suggest which phenotypic CHD sub-types have the greatest 
diagnostic yield.9,10,11  Hence, the objectives of this prospective cohort study, systematic 
review and meta-analysis were to determine the yield of ES over CMA/karyotype in; (i) any 
prenatally diagnosed CHD; (ii) isolated CHD; (iii) CHD associated with ECAs and; (iv) CHD 
dependent on phenotypic subgroup.   
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METHODS 
Extended PAGE Cohort   
CODE assessed the extended cohort of the published Prenatal Assessment of Exomes and 
Genomes (PAGE) study which included 850 trios (fetus and parents) that underwent ES 
analysis when a fetal structural anomaly was detected on ultrasound.5  This prospective 
extended cohort study recruited between October 2014 and May 2018 across 34 fetal 
medicine centres in England and Scotland, using the West Midlands Genetic Research 
Laboratory (WMGRL) as their laboratory hub and then through the Wellcome Trust Sanger 
Institute (for exome sequencing).5  Eligibility criteria included; (i) prenatal detection of an 
anomaly after 11-weeks’ gestation including an increased nuchal translucency (NT) (>4mm); 
(ii) an invasive test having been performed; (iii) informed written consent obtained from 
both parents for testing and both were >16-years and; (iv) negative CMA or karyotype 
testing.  Study methodology is as documented in the original published study but briefly 
utilized a standard ES approach with variant interpretation based upon a targeted virtual 
gene panel for developmental disorders encompassing 1628 genes.5  Phenotypes of all cases 
were classified using Human Phenotype Ontology (HPO) terms and those which were 
cardiac related were selected.  Following manual review of free-text descriptions, miscoded 
terms and small muscular ventricular-septal defects (VSDs) were removed.  CHD was initially 
further classified into ‘isolated’ and ‘multi-system’ with a HPO approach to coding additional 
ECAs, including fetal growth restriction, single umbilical artery and nuchal thickening but not 
an elevated first trimester NT.  Cardiac phenotypes were described by fetal medicine 
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specialists and sonographers and confirmed by fetal cardiologists using the Viewpoint® 
Version 5.6.16 GE Healthcare, 2012 and were subsequently coded using the American Heart 
Association/American College of Cardiology (AHA/ACC) criteria as; (i) shunt lesions; (ii) left-
sided obstructive lesions; (iii) right-sided lesions and; (iv) complex lesions.12  Two clinicians 
reviewed each classification for concordance (F.M. and M.D.K).  Pathogenic variants and 
variants of uncertain significance (VUS) where the American College of Medical Genetics 
classification had been agreed upon at the clinical review panel were included in the final 
list of variants.13  Incidental findings (IFs) were not reported.  The study was approved by the 
Research and Development offices and Research Ethics Committees at each institution and 
obtained ethical approval from the Research and Development offices and Research Ethics 
Committees at the West Midlands – South Birmingham (ref: 13/WM/1219) and each 
institution.   
 
Data Sources 
A systematic review was conducted in a standardized fashion in line with PRISMA 
guidance.14  A systematic electronic search of MEDLINE, CINAHL, EMBASE and 
clinicaltrials.gov was performed from January 2000 (as ES was not available prior to this) 
until October 2019.  MeSH keywords with word variations of the terms ‘exome sequencing’ 
and ‘prenatal’ were used in an attempt to capture as many relevant studies as possible.  
Alternative terms for ES included ‘exome sequencing, whole’; ‘exome sequencing, 
complete’; ‘whole genome sequencing’ and ‘sequence analysis, DNA’.  Alternative terms for 
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prenatal included ‘fetal’; ‘fetus’ and ‘antenatal’.  Experts were also contacted and 
bibliographies of all relevant papers were searched.  Studies not in the English language 
were translated.  The search strategy is available from the corresponding author on request.  
This systematic review was registered prospectively with PROSPERO No. CRD42019140309.  
 
Eligibility criteria for study selection and data extraction 
All study abstracts were screened by two reviewers (F.M. and M.D.K.) and full text articles 
were subsequently reviewed where further information was required.  Studies were 
selected if; (i) they included three or more cases of CHD undergoing ES; (ii) testing was 
initiated based upon a prenatal ultrasound-based phenotype and; (iii) CMA/ karyotype 
testing was negative.  In cases where ES was initiated postnatally, these were only included 
where testing was based upon the prenatal phenotype.  Data extracted from studies where 
obtainable included: ultrasound phenotype, ES approach, genomic variants, source of fetal 
DNA, turnaround time for testing, fetal outcome, maternal age and gestation at testing.  An 
ES result was deemed positive only if it was graded IV to V ‘likely pathogenic’ or ‘pathogenic’ 
and determined to be causative of the phenotype.  VUS and IFs were reported separately.13  
 
Quality assessment and data synthesis 
The incremental yield or risk difference of ES over CMA/karyotype was calculated for each 
study with 95% confidence intervals and as a meta-analysis for; (i) all CHD; (ii) subgroup 
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analyses of isolated and multisystem CHD with only studies included in the latter when the 
presence or absence of CHD were available from the data.  Cases were stratified as per the 
aforementioned cohort study.  Risk differences from each study were pooled using a 
random effects model throughout to estimate the overall yield and the yield for isolated and 
multi-system CHD using RevMan version 5.3.4 (Review Manager, The Cochrane 
Collaboration, Copenhagen, Denmark) via a previously published method which facilitated 
calculation of the incremental yield with adjustment for ‘zero’ values from negative CMA 
testing which was applicable to all included studies.15  Findings were displayed as forest 
plots with corresponding 95% confidence intervals.  Heterogeneity was assessed graphically 
and statistically (Higgins’ I2) and a sub-analysis was performed including studies with >20 
cases to determine if results differed significantly.  Publication bias was assessed graphically 
using funnel plots (also generated by RevMan version 5.3.4 and demonstrated as 
Supplementary Figure 1a-c).  Quality assessment of studies was assessed using a modified 
Standards for Reporting of Diagnostic Accuracy (STARD) criteria.  The quality criteria 
deemed most important to optimise accuracy were; (i) if trio analysis was performed; (ii) 
ACMG criteria for variant interpretation and; (iii) Sanger validation of variants.13  Due to the 
limited number of studies available, beyond the pre-defined inclusion criteria, quality 
assessment could not be incorporated into the analysis so as the optimise the number of 
cases included.13,16, 17   
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RESULTS 
Extended PAGE Cohort 
Of 850 fetuses undergoing trio ES with prenatally detected structural anomalies, there were 
n=197 (23.2%) CHD cases in total, of which 61.9% (n=122) were isolated and 38.1% (n=75) 
associated were with ECAs.  Where documented (n=190), the source of fetal DNA was; a) 
chorionic villi 15.8% (n=30); b) amniocytes 81.1% (n=154) or; c) lymphocytes 3.2% (n=6).  G-
banding karyotype was performed 3.0% (n=6) of cases, with CMA in the remainder.  The 
diagnostic yield of ES in each group (excluding VUS) was 12.7% (n=25/197) all CHD, 11.5% 
(n=14/122) isolated CHD and 14.7% (n=11/75) in multisystem CHD respectively (p=0.81).  In 
instances of multi-system CHD with a pathogenic variant, the commonest systems affected 
were those affecting growth, the nervous system and face (all 45.5% n=5/11).  There were 
not enough cases to identify a dominant sub-classification of CHD hence this was explored 
further in the systematic review.  The overall incidence of VUS was 5.1%.  
 
Systematic review and meta-analysis 
In all instances where a study was suitable for inclusion but data was incomplete, the 
corresponding author was contacted (n=6), of which three responded and two provided 
complete data.6,18  Authors of the second largest included study, the Petrovski, et al. 
Columbia University-based study, provided a completed dataset on their CHD cohort as an 
extended version of their original study.6  In addition to both the extended PAGE cohort 
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study and the extended Petrovski, et al. study6, a further 16 studies met the overall 
selection criteria, leading to a total of 18 studies, as demonstrated in Figure 1.5,6, 9-11, 18-30  
Table 1 outlines the study characteristics and Figure 2 outlines the overall quality 
assessment of all studies included.  There was one study where ES was targeted using a CHD 
panel while the remainder used a whole ES approach.9  Not all studies broke CHD down into 
isolated/multi-system or distinctive phenotypes as demonstrated or described the cardiac 
phenotype [Table 1].  
 
Combined cohort outcomes 
18-studies were included, encompassing n=636 CHD cases undergoing ES, of which n=529 
stated whether CHD was isolated or associated with ECAs.  Hence, 54.4% (n=288/529) of 
cases were isolated and 45.6% (n=241/529) multi-system CHD.  Where available, the mean 
maternal age and gestation at the time of  testing was 30 (+/-3.5 SD) years and 22 (+/-4.7) 
weeks.  The primary genetic test performed prior to ES was CMA 98.0% (n=623/636) with 
the predominant source of fetal DNA from amniocytes 54.6% (n=322/590).  Of the n=18 
studies included, information regarding the originally recruited cohort prior to 
CMA/karyotype results were stated for n=5 studies.5,6,9,11,24  These revealed that there was 
an abnormal CMA/karyotype in 21.0% (n=1109/5285) of cases.  Where stated (n=261), the 
median turnaround time for ES was 42 (range 7-82) days and pregnancy outcome was 
reported in n=341, of which livebirth 47.8% (n=163) and termination of pregnancy 46.3% 
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(n=158) were the commonest outcomes.  Where reported, the pooled incremental yields of 
VUS and IFS were 26% (95% CI, 14-39% p=0.0001) and 8% (95% CI, 0-17% p=0.0001).  
 
Incremental yield of pathogenic variants 
The pooled incremental yields (excluding VUS) from all 18-studies are illustrated in the 
forest plots for (i) all ; (ii) isolated and; (iii) multi-system CHD [Figure 3(a-c)].  In the cases of 
(ii) and (iii) 13 and 15-studies included relevant cases for inclusion.  Incremental yields for 
the aforementioned groups were 21% (95% CI, 15-27% p=0.0006), 11% (95% CI, 7-15% 
p<0.00001) and 37% (95% CI, 18%-56% p<0.00001) respectively.  The sub-analysis of studies 
with >20-cases (n=8) is demonstrated in Supplementary Figures 2a-c with corresponding 
funnel plots (Supplementary Figures 3a-c).  Findings did not differ significantly from the 
primary analysis, apart from multi-system CHD, where the incremental yield was greater at 
49% (95% CI, 17-80% p=0.003).  Where gestational age was recorded in isolated CHDs the 
incremental yield for those diagnosed after 15-weeks’ gestation was greater than for all 
cases at 24% (95% CI, 7%-41%, p=0.002, I2=68%).  In instances of multi-system CHD in the 
primary analysis, the commonest ECAs associated with a pathogenic variant were those 
affecting the genitourinary system 44.2% (n=23/52), nervous system 34.6% (n=18/52) and 
face 34.6% (n=18/52).  In multisystem CHDs, where a pathogenic variant was detected and 
the specific ECA was documented (82.7%, n=43/52), there was one instance (2.3%, n=1/43) 
where a ‘minor ECA’ was present (single umbilical artery), with the remainder being major 
or affecting two or more systems.   
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On classification as per AHA/ACC criteria for all CHD, shunt lesions (septal anomalies and 
total anomalous pulmonary venous drainage) had the greatest pooled incremental yield of 
pathogenic variants 41% (95% CI, 19-63% p=0.003),  followed by right-sided 26% (95% CI, 9-
43%, p=0.001), complex 23% (95% CI, 9-36%, p=0.001) and left-sided obstructive lesions 
18% (95% CI, 0-35% p=0.02).  Where documented, pathogenic variants are described in 
Supplementary Table 1.  Where pathogenic variants were documented (n=96/111; 86.5%), 
the commonest genetic syndromes identified were those of Kabuki syndrome (n=19/96; 
19.8%), CHARGE (Coloboma-Heart defects-Atresia choanae-Retardation of growth-genital 
abnormalities-ear abnormalities) syndrome (n=8/96; 8.3%), Noonan syndrome (n=6/96; 
6.3%) and Primary Ciliary Dyskinesia (n=6/96; 6.3%).  In syndromes where CHD was typically 
described as being multi-system in nature, in 54.1% (n=20/37) of such syndromes only an 
isolated CHD was detected prenatally e.g. Adams-Oliver, CHARGE, Kabuki and Simpson-
Golabi-Behmel syndrome.  In the majority of instances pathogenic variants occurred de 
novo and in autosomal dominant (monoallelic) disease genes (68/96; 70.8%) 
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DISCUSSION  
This is the first systematic review assessing the yield of antenatal ES in prenatally diagnosed 
CHD in which CMA/karyotype was negative.  The results of this study show an apparent 
incremental yield of ES in CHDs, particularly for shunt lesions and multi-system CHD.  Most 
pathogenic variants occurred de novo  in monoallelic disease genes with a high incidence of 
Kabuki syndrome.  The majority were reported in syndromes which typically present with 
ECAs yet presented with an isolated CHD.  
 
The diagnostic yield from our cohort study was modest compared to other studies in the 
meta-analysis.  This is potentially secondary to several factors; (i) bias in case selection – 
smaller series may have had an element of selection bias only selecting cases with positive 
results;31 (ii) the proportion of multi-system CHD – the greater the proportion, the higher 
the overall yield and; (iii) the sequencing approach used e.g. targeted or whole exome; the 
series from Hu et al. (n=44 CHD cases)9 revealed a high diagnostic yield when a targeted 77 
cardiac panel approach was used (n=7; 15.9%).  Of the 77 genes, only 5 genes were not 
included in the PAGE study panel, none of which were found to be causative in the Hu, et al 
study.9  While use of targeted gene panels potentially provide a greater yield in a shorter 
time frame, users must exert caution as they are primarily based upon postnatal and not 
prenatal phenotypes.31 
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The greater incremental yield with ES associated with multi-system vs. isolated CHD is 
similar to the pattern seen with aneuploidy and CNV, as is the case with shunt lesions and 
left-sided obstructive lesions.15  Shunt lesions tend to be associated with ECAs which is 
probably why the diagnostic yield with ES in this group is most significantly enriched.3,4  The 
predominance of de novo variants in monoallelic disease genes is also in keeping with 
published evidence.3,7,8,32  It is interesting that the most common syndromes unveiled in this 
study were those of Kabuki and CHARGE.  Kabuki syndrome has a highly variable 
phenotype.33  There is limited evidence with regards the prenatal presentation and the high 
incidence as seen in this study has not been previously reported, although an overall 
association with postnatally diagnosed left-sided CHD has been established.33-35  Both 
CHARGE and Kabuki syndromes are caused by pathogenic variants in genes encoding 
proteins implicated in chromatin function and gene regulation.36 There is a potential link 
between these syndromes with an association between DNA methylation targets in their 
gene-specific signatures.36  This reflects that epigenetic dysregulation is the commonest 
pathway responsible for the greatest proportion of CHD where pathogenic variants were 
uncovered in this series.36  
 
The strength of this study is the robust and systematic methodology utilised so that all 
available studies were included to limit selection bias.  International collaboration between 
the two groups publishing the two largest series of prenatal congenital anomalies and ES 
has optimised the numbers.  By excluding studies where phenotypes were based on 
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postnatal examination, our study is specific for prenatal ES testing focusing on ultrasound 
detected CHD.  The quality of included studies based upon pre-specified criteria was optimal 
due to the high number which had an ES approach to testing, variant interpretation based 
upon ACMG criteria and Sanger sequencing validation which meant most had a uniform and 
hence comparable approach.13   
The main study limitation was high heterogeneity.  This was likely caused by differing 
platforms used, as well as small-study effects reflected in asymmetry within the funnel 
plots.  However, limiting the inclusion of studies to those with >20 cases didn’t show a 
significant difference in incremental yield.  There is currently no recognised classification 
system for prenatal CHD hence we selected an adult-based system.12  This  meant that rare 
CHD associated with high instances of perinatal demise could not be appropriately 
classified.  Alternative classification systems were considered and experts were consulted, 
however the categories included were too broad which mean that due to a restricted 
number of cases where the phenotype was described, relevant associations would not be 
identified.37,38   
 
The challenges of ES in prenatally diagnosed CHD include; (i) the limited phenotype available 
from ultrasound imaging.  Although concordance is generally high, more information is 
typically gathered from detailed postnatal examination1,39,40; (ii) whether targeted panels or 
a whole ES approach should be used and; (iii) that CHD tends to be a highly heterogenous 
group of anomalies with multi-gene and multifactorial pathologies which may not be 
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unveiled with genomic testing.3  Further novel gene discovery may lie in epigenomic or 
genomic changes encoding proteins involved in chromatin re-modelling, the RAS signalling 
pathway, ciliary function and sarcomere achitecture.2  A further challenge with ES in 
pregnancy is the time constraint which it poses.  Several studies made an a priori decision to 
report the results after the end of the pregnancy and thus the clinical/laboratory pathways 
were not accelerated to achieve real time results to individual members of the study.  
However, several fetal ES studies have reported delivering results in a timely fashion to 
inform pregnancy management,28 and a rapid fetal ES service will shortly be introduced in 
the English National Health Service for the diagnosis of monogenic disorders.  As well as 
turnaround time, the clinical utility of ES in CHD is dependent not just on the prospective 
targeting of phenotypes but also robust bioinformatics filtering within accredited genomic 
laboratories and detailed analysis by clinical multidisciplinary review groups to assess and 
determine causative variants.  Pre-test counselling must be accurate, clear and 
comprehensive with consideration given to ethical challenges.  Without such robust 
bioinformatics and clinical screening of variants, prenatal ES should not be offered or used 
in clinical practice.41,42  
 
In conclusion, despite the apparent incremental yield of prenatal ES in CHD, the 
routine application of such a policy would require the adoption of robust 
bioinformatic, clinical and ethical pathways.  Whilst the highest yield is with multi-system 
anomalies, consideration may also be given to performing ES in the presence of isolated 
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CHDs.  Further work is required to explore the benefits and challenges of delivering targeted 
or whole exome analysis. Clinical guidelines must be introduced to ensure that testing is 
correctly implemented.   
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Figure legends 
Figure 1 Flowchart demonstrating included studies 
Figure 2 Quality assessment for studies in the systematic review (n=18) using modified 
STARD criteria 
Figure 3 Forest plots of incremental yield by exome sequencing over karyotype/microarray 
in fetuses with prenatally detected cardiac anomalies in (a) all; (b) isolated and; (c) multi-
system cardiac anomalies. Only first author of each study is given.  [CMA = chromosome 
microarray; M–H = Mantel–Haenszel].  
Figure S1 Funnel plots of ALL studies reporting on incremental yield of exome sequencing 
over microarray/karyotyping in fetuses with congenital heart anomalies (CHAs) 
- Figure S1a All CHD 
- Figure S1b Isolated CHAs 
-  Figure S1c  Multisystem CHAs 
Figure S2 Forest plots of studies with >20 cases reporting on reporting on incremental yield 
of exome sequencing over microarray/karyotyping in fetuses with congenital heart disease       
(CHD) 
- Figure S2a All CHD 
- Figure S2b Isolated CHD 
- Figure S2c Multisystem CHD 
Figure S3 Funnel plots of studies with >20 cases reporting on incremental yield of exome 
sequencing over microarray/karyotyping in fetuses with congenital heart disease (CHD)   
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- Figure S3a All CHD 
- Figure S3b Isolated CHD 
- Figure S3c Multisystem CHD 
Table legends 
Table 1 Study characteristics and rates of pathogenic variants and variant of uncertain 
significance [CE=Clinical Exome; N/S = not-stated; WES=Whole exome sequencing *coverage 
not stated]  
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Table 1- Study characteristics and rates of pathogenic variants and variant of uncertain 
significance [CE=Clinical Exome; N/S = not-stated; WES=Whole exome sequencing *coverage 
not stated] 
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NimbleGen SeqCap EZ targeted capture 
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98.3% of the bait regions covered at a 
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Normand et al. 
28 
WES Trio Coverage 150X  
Roche NimbleGen capture 









Petrovski et al. 6 WES Trio 
Nimblegen SeqCap EZ capture + Illumina 
Hiseq 2500 
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WES Parents only 80X coverage 
Agilent capture + Illumina HiSeq 2500 or 
NextSeq500 
Only include het rare  (MAF<0.001) 
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